You are viewing: Poland Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The Poland Leukapheresis Market was valued at $0.41 Million in 2026 and projected to reach to $0.55 Million by 2031, representing a compound annual growth rate of CAGR 6.2%. Poland's leukapheresis market demonstrates moderate but consistent growth potential, driven by modernization of healthcare infrastructure and increasing prevalence of hematologic conditions.

Poland Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Poland Leukapheresis Market Trends and Insights

  • Poland's healthcare infrastructure continues to modernize, with increasing adoption of advanced cell separation technologies in hematology and oncology centers.
  • The market growth in Poland is driven by rising prevalence of hematologic malignancies and expanding access to CAR-T cell therapies, which rely heavily on leukapheresis procedures. During the 2026–2031 forecast period, Poland is expected to see steady demand for leukapheresis equipment and consumables as clinical centers invest in cell therapy capabilities.
  • Poland's participation in European Union healthcare initiatives and cross-border patient mobility further support market expansion.
  • The country's focus on precision medicine and immunotherapy adoption positions Poland as an emerging hub for cell-based treatments within Central Europe..

Key Market Statistics

  • CAGR (2026-2031) CAGR 6.2%
  • Market Size, 2026 ~USD 0.41 Million
  • Forecast, 2031 ~USD 0.55 Million
  • Country Poland

Poland Leukapheresis Market Overview

Market Size & Growth :

Poland's leukapheresis market is valued at $0.41 million in 2026, expanding to $0.55 million by 2031 at a CAGR of 6.2%, reflecting steady adoption of cell separation technologies in Polish healthcare facilities.

Healthcare Infrastructure Modernization :

Polish hematology and oncology centers are increasingly investing in advanced leukapheresis equipment as part of broader healthcare modernization initiatives, supporting improved patient outcomes in blood disorder treatment.

Rising Disease Prevalence :

Growing incidence of hematologic malignancies and blood disorders in Poland is driving demand for leukapheresis procedures, particularly in major medical centers and university hospitals across Warsaw, Krakow, and Wroclaw.

Reimbursement & Access :

Poland's National Health Fund (NFZ) coverage of leukapheresis procedures for eligible patients is expanding access to treatment, supporting market growth and encouraging adoption among regional healthcare providers.

Poland Leukapheresis Market Dynamics

  • The country's integration into European healthcare standards and rising investment in oncology centers are creating favorable conditions for advanced cell separation technology adoption.
  • Polish hospitals are progressively upgrading their capabilities to meet international treatment protocols, particularly for leukemia and lymphoma management.
  • Collaboration with European medical centers and access to international clinical guidelines further support market expansion.
  • By 2031, Poland is expected to establish itself as a growing market for leukapheresis within Central Europe, with increased penetration in major urban medical centers and regional hospitals..

Related Ecosystem

Key Takeaways

  • Poland's leukapheresis market is valued at $0.41 million in 2026 and will reach $0.55 million by 2031 at a 6.2% CAGR.
  • Poland's healthcare modernization and EU integration are driving adoption of advanced cell separation technologies.
  • Rising hematologic malignancy prevalence and CAR-T cell therapy expansion are key growth catalysts in Poland.
  • Poland is emerging as a Central European hub for cell-based immunotherapy and precision medicine applications.

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

Poland Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

POLAND: LEUKOPAKS MARKET, BY END USER, 2024–2031

Segment20242025202620272028202920302031CAGR (%)
ACADEMIC & RESEARCH INSTITUTES2.082.272.472.712.973.263.593.969.8
CONTRACT RESEARCH ORGANIZATIONS0.130.140.150.160.170.180.20.217.4
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES0.610.670.750.830.921.031.151.2811.4
TOTAL2.823.083.373.694.064.474.935.4510.1

POLAND: LEUKAPHERESIS MARKET, BY END USER, 2024–2031

Segment20242025202620272028202920302031CAGR (%)
ACADEMIC & RESEARCH INSTITUTES0.060.070.070.080.080.090.090.15.8
BLOOD COMPONENT PROVIDERS & BLOOD CENTERS0.230.240.260.280.30.320.340.377.3
HOSPITALS & TRANSFUSION CENTERS0.120.130.140.150.150.170.180.196.6
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES0.040.040.040.040.050.050.050.054.7
TOTAL0.450.480.510.550.580.620.660.716.7

Target Audience

  • Medical Device Manufacturers : Companies manufacturing leukapheresis equipment need Poland-specific market data to assess market size, growth potential, and competitive opportunities for product launches and distribution partnerships.
  • Healthcare Investors & PE Firms : Investment professionals evaluating healthcare opportunities in Central Europe require detailed Poland market analysis to assess valuations, growth trajectories, and investment returns in the leukapheresis sector.
  • Hospital & Clinic Administrators : Polish healthcare facility leaders need market insights to justify capital expenditures on leukapheresis equipment, understand adoption trends, and benchmark against peer institutions.
  • Pharmaceutical & Biotech Companies : Organizations developing cell therapies and CAR-T treatments require Poland market data to understand treatment infrastructure, patient populations, and commercial viability for their therapeutic solutions.
  • Healthcare Consultants & Analysts : Consulting firms and research analysts covering Central European healthcare markets need Poland-specific leukapheresis data to support client advisory work and market intelligence reports.

Key Companies in the Poland Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

Reasons to Buy this Report

  • Poland-Specific Market Sizing : Obtain precise market valuation data for Poland ($0.41M in 2026, $0.55M in 2031) with detailed CAGR analysis to support investment decisions and market entry strategies in Central Europe.
  • Healthcare Infrastructure Insights : Understand Poland's modernization trajectory in hematology and oncology centers, identifying key facilities and regions with highest adoption potential for leukapheresis technologies.
  • Competitive Landscape Analysis : Gain intelligence on market players, distribution channels, and competitive positioning specific to Poland's healthcare system, including NFZ reimbursement dynamics and hospital procurement patterns.
  • Growth Driver Identification : Access detailed analysis of Poland-specific factors driving market growth, including disease prevalence trends, regulatory environment, and healthcare spending patterns through 2031.
  • Strategic Market Entry Planning : Leverage Poland-focused forecasts and market segmentation to develop targeted go-to-market strategies, partnership opportunities, and expansion plans in the Central European region.

Frequently asked questions

What is the current size of the leukapheresis market in Poland?

Poland's leukapheresis market is estimated at $0.41 million in 2026.

What is the projected market size for leukapheresis in Poland by 2031?

Poland's leukapheresis market is forecast to reach $0.55 million by 2031.

What is the growth rate of the leukapheresis market in Poland?

Poland's leukapheresis market is expected to grow at a compound annual growth rate of 6.2% from 2026 to 2031.

What factors are driving leukapheresis market growth in Poland?

Key drivers include rising hematologic malignancy prevalence, expanding CAR-T cell therapy access, healthcare infrastructure modernization, and EU healthcare integration initiatives.

How does Poland's leukapheresis market compare to other European countries?

Poland represents an emerging market within Central Europe, with steady growth supported by healthcare modernization and increasing adoption of cell-based immunotherapies aligned with broader European trends.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status